Brookline Capital Management Estimates CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Brookline Capital Management issued their FY2029 EPS estimates for Caribou Biosciences in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $16.92 per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

A number of other research analysts have also recently issued reports on the company. Citigroup lowered their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Bank of America dropped their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

CRBU stock opened at $1.72 on Wednesday. The firm has a 50 day moving average price of $2.03 and a 200-day moving average price of $2.00. Caribou Biosciences has a 52-week low of $1.50 and a 52-week high of $8.33. The firm has a market capitalization of $155.75 million, a price-to-earnings ratio of -1.04 and a beta of 2.34.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRBU. The Manufacturers Life Insurance Company lifted its holdings in shares of Caribou Biosciences by 16.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock valued at $60,000 after buying an additional 5,244 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Caribou Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after acquiring an additional 6,768 shares during the period. Erste Asset Management GmbH purchased a new position in Caribou Biosciences in the third quarter worth about $28,000. American Century Companies Inc. grew its stake in shares of Caribou Biosciences by 15.2% during the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after purchasing an additional 16,530 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $30,000. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.